suggested that the morbidity and mortality rates after VBA stent placement are as high as 30%, whereas in other series significantly lower rates of permanent neurological morbidity have been reported. 13, 24, 32 Typically, long, eccentric lesions with severe luminal narrowing (that is, Mori 26 Type C lesions) have the highest rate of complications, with procedural failure rates of 70%. Additionally, angioplasty alone has been associated with recurrence rates of stenosis ranging from 9 to 25%. 9, 45 These shortcomings led us to investigate the effectiveness of stent placement procedures. As our experience with intracranial stent placement developed, in conjunction with data in the coronary literature 36 on disruption of plaque by angioplasty, we believed that we could minimize morbidity by reducing the percentage of stenosis in high-grade lesions, allowing time for the vessel to heal from the angioplasty, and then proceeding with stent placement if necessary.
To elucidate the risks associated with stent-assisted angioplasty of the posterior intracranial cerebrovasculature and to determine whether staging of this procedure (angioplasty followed by repeated angioplasty, with stent placement delayed by at least 1 month) reduces procedure-related morbidity while increasing rates of procedural success, we retrospectively reviewed our experience in a series of patients with severe, medically refractory symptomatic VBA stenosis.
Clinical Material and Methods
During a 35-month study period between February 1999 and January 2002, eight consecutive patients underwent planned stent-assisted angioplasty of the intracranial posterior circulation. Staged stent-assisted angioplasty was planned for these patients because the extent and degree of stenosis in their symptomatic, atherosclerotic lesions portended an excessive procedure-related risk. The degree of stenosis, recent onset of symptoms (unstable plaque), vessel tortuosity, and lesion length and morphological characteristics were contributing factors in determining the procedure-related risk. We reviewed these patients' medical records for the following parameters: age, sex, location of symptomatic lesion, degree of stenosis before and after angioplasty and stent placement, clinical presentation, comorbid conditions, antiplatelet and/or anticoagulation regimen, procedure-related complications, clinical and radiological follow up, and use of glycoprotein IIb/IIIa agents (abciximab or eptifibatide). Procedural success was defined as more than 50% endoluminal revascularization of the stenotic lesion (compared with the parent vessel lumen) after stent deployment, with resolution of symptoms at the time of clinical or angiographic follow up.
Measurements of lesion length, width, and percentage of stenosis (determined by dividing the width of the lesion by the width of the normal proximal parent vessel and multiplying by 100) were calculated using commercially available software (Image-Pro Plus version 3.0; Media Cybernetics, Inc., Silver Spring, MD). Angiograms were scanned using the same software package, and lumen diameters were calibrated based on the measurements of the parent vessel diameter that had been recorded in the angiography suite during the procedure.
Operative Technique
At our institute, endoluminal revascularization of the intracranial posterior circulation is typically performed in an awake patient with the aid of midazolam and/or fentanyl as sedatives. The procedure is begun by placing a diagnostic catheter in the VA, ipsilateral to the lesion. This catheter is advanced distally over a hydrophilic 0.035-in wire into the VA origin. Before the catheter is advanced into the VA origin, a single-dose bolus of heparin (70 g/kg) is administered to achieve a target activated coagulation time within the range of 250 to 300 seconds. Roadmapping techniques are used to guide the wire to the C1-2 vertebral level. The wire is left in place, and the diagnostic catheter is exchanged for a guide catheter. In the cases presented here, glycoprotein IIb/IIIa inhibitors were administered during the procedure and continued for the next 12 hours, and heparin was given as a bolus dose of approximately 50 g/ kg to achieve a target activated coagulation time of 225 to 250 seconds. 21, 33 After the proper activated coagulation time has been achieved, high-magnification roadmapping techniques are used to advance first a 0.014-in navigational microwire, and subsequently a microcatheter, across the lesion. The microcatheter is seated in a normal distal branch of the stenotic vessel and the wire is exchanged for a stiffer, 300-cm coronary wire. The microcatheter is then removed.
In the cases presented here, the stenotic lesions were too severe and/or were believed to be too tortuous to cross safely with a stent without first performing angioplasty to increase the cross-sectional diameter of the arterial lumen. We chose the shortest angioplasty balloon that would fully cover the lesion and inflated this balloon to approximately 50 to 75% of the parent vessel lumen. A slow inflation was used, as has been described by others. 9 The balloon was removed, and an angiographic study was performed. Stents were selected according to the following factors: length of the lesion, vessel diameter, and proximal vessel tortuosity. Although numerous types of stents are currently available, the choices were fewer at the time some of these patients were treated.
For adjunctive stent placement, the device is advanced toward the lesion, such that the tip of the guide catheter can be seen in the fluoroscopic field at all times during the procedure. The appropriate balloon-mounted stent is advanced over the wire across the stenotic area. The stent is deposited by toggling the insufflator at the appropriate nominal pressure, after which the stent delivery system is removed. Selective angiography through the guide catheter is then performed to visualize successful stent placement, degree of residual stenosis, and presence of dissection or thrombus.
Four days before angioplasty and stent placement, a regimen of aspirin (325 mg/day) and clopidogrel (75 mg/day) is prescribed for the patients. Also, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are included in the patient's daily medical regimen. Findings on serial angiographic studies indicate an improvement in intracranial stenosis after daily administration of these inhibitors, which may augment the intrinsic lytic system. 
Results
The ages of the eight men in this study ranged from 52 to 90 years (mean 68 years, Table 1 ). These patients presented with symptoms of VBA insufficiency (five patients), stroke (two patients), or both (one patient). Symptoms of VBA insufficiency included a constellation of ailments such as dysarthria, vertigo, diplopia, motor and sensory dysfunction, syncope, and gait instability. In all patients treatment with antiplatelet and/or anticoagulant regimens had failed.
Lesion characteristics are presented in Table 2 . All lesions involved the intracranial posterior circulation. Four lesions involved the midportion of the BA, three others were at the VB junction, and one was at the proximal intracranial segment of the VA. The mean diameter of the distal parent vessel lumen was 2.85 mm, compared with the mean lesion width of 0.63 mm. The mean preangioplasty stenosis was 77% (range 65-90%); the mean postangioplasty stenosis was 54% (range 32-69%); and the mean stenosis immediately after stent placement was 30% (range 20-45%).
Endovascular angioplasty balloons and stents used and complications encountered are presented in Table 3 . One patient (Case 1) suffered a vessel dissection during balloon access, necessitating immediate stent placement. In a second patient (Case 7) tortuous vessel anatomy precluded the successful delivery of a stent. A third patient (Case 5) had excellent resolution of the stenosis and optimal vessel patency after angioplasty alone, as documented by postprocedural angiography, and did not require stent placement (Table 3) . No permanent neurological complications occurred; however, in one patient (Case 1) transient hemiparesis and aphasia developed due to a pontine infarction following a BA dissection that occurred when we passed the angioplasty balloon. This patient improved to his baseline neurological status over the next few months. In one patient (Case 6) a retroperitoneal hematoma developed that required surgical repair of the femoral artery and blood transfusions. There was one other hematoma in the groin site; this one did not require surgical intervention.
Clinical follow-up results obtained from an office visit or telephone interview were available for all eight patients, with a mean follow-up duration of 26 months (range 6-36 months). None of these patients experienced further symptoms attributable to the treated intracranial stenosis, and in one patient (Case 1) there was an improvement in hemiparesis that had resulted from a stroke that occurred before he underwent the endovascular procedure. This patient recently suffered an unrelated right carotid artery distribution stroke, and another (Case 7) died of an acute myocardial infarction 4 months after attempted stent placement.
Angiographic follow-up results were available in four patients at a mean interval of 27 months (range 7-35 months). Of patients treated with angioplasty alone, one (Case 2) had 45% residual stenosis, the second (Case 5) had no evidence of significant stenosis, and the third (Case 7) had 60% residual stenosis ( Table 2 ). The patient in Case 3 had worsening residual stenosis, from 40 to 60%, but remained asymptomatic. The patient in Case 8 experienced some gait imbalance during the interval between angioplasty and stent placement. These symptoms were similar to those with which he presented, and it is unclear whether he was suffering persistent sequelae from previous ischemia. These symptoms gradually improved after stent placement, and he remains asymptomatic as of the last follow-up examination.
Discussion
Over the past 2 years, there has been marked advancement in stent technology. Clinicians are now able to deliver more pliable stents to the distal intracranial VB vasculature. There are cases in which treatment options are limited by excessive proximal tortuosity of or poor access to the lesion; however, with combined surgical procedures that expose the VA in the C1-2 region or the foramen magnum, most atherosclerotic lesions of the intracranial VA or BA can now be effectively treated with endoluminal revascularization techniques. 41 
Limitations of Intracranial Angioplasty
Stent placement for medically refractory VBA stenosis 9 dissection occurred in 14%, repeated angioplasty was necessary in 8%, and residual stenosis exceeding 50% occurred in 16%. In a review of 12 patients reported on by Terada, et al., 40 the mean rate of posttreatment stenosis was 44%, with complications occurring in four patients.
An important finding by Mori, et al., 26, 29 is that lesion morphological features are predictive of restenosis and complication rates. Stenotic lesions that were long, eccentric, and ectatic were associated with greater rates of restenosis and lower rates of procedural success than those that were short, focal, and concentric. Although no evidence exists to demonstrate the superiority of stent placement over angioplasty alone in the intracranial circulation, available data indicate that it is superior for coronary vessels of similar caliber to the VA and BA. In one study of 43 lesions in coronary vessels less than 2.5 mm in caliber, 76% of patients remained symptom free or had patent target sites after coronary artery stent placement. 20 Similar results were demonstrated by Morice, et al., 30 with 25% of patients requiring repeated intervention after stent placement in small coronary vessels. Perhaps the best evidence of the superiority of stent placement over angioplasty in small vessels (Ͻ 3 mm) is gleaned from the results of the Stent Restenosis Study. Stent-assisted revascularization of coronary vessels resulted in a statistically significantly larger postprocedural lumen diameter in the periprocedural period and at the 6-month follow-up review, compared with angioplasty alone. Furthermore, restenosis of 50% or more occurred in 55% of the angioplasty group and in only 34% of the group receiving stents. The 1-year event-free survival rate was 78% in the stent-treated group and 67% in the group that underwent angioplasty. Although the coronary vasculature is histologically different from the intracranial vasculature, we cannot ignore these findings and we believe that stent treatment is likely to be superior to angioplasty alone.
Plaque Subtype Worsened by Aggressive Angioplasty
In a report about the histological subtyping of coronary atherosclerotic lesions, Stary, et al., 36 described the histological features of unstable plaques (on a I-VI grading scale). In a Type IV lesion, dense accumulation of extracellular lipid occupies a region of the intima, with no thrombosis or defects of the lesion surface. These are quite dangerous because they may easily progress to Type VI lesions (discussed later) and result in symptomatic occlusive disease. The region between the lipid core and the lesion surface contains proteoglycans, macrophage foam cells, and smooth-muscle cells, which can easily be exposed to blood from fissures in the intimal surface brought on by aggressive angioplasty or immediate stent placement. Submaximal angioplasty has a lower likelihood of creating breaks in the intimal surface, thereby preventing exposure of the lipid core and smooth-muscle cells to the bloodstream and coagulation cascade. Type V lesions, or fibroatheromas, have prominent new fibrous connective tissue with multiple layers of smooth-muscle cell proliferation overlying regions of the lipid core. These lesions tend to be thicker, with the fibrocellular response intermingled with calcium and lipid content. Type VI lesions, or complicated lesions, occur when Type IV or V lesions develop breaks in the integrity of the intimal surface or when they develop hemorrhage and/or thrombosis. The majority of symptomatic lesions occur following the progression to complicated (Type VI) plaques.
If we assume that similar plaque organization occurs in the intracranial circulation, aggressive angioplasty is likely to lead to disruption of the fragile plaque surface and increase the risk of progression to Type VI lesions. In turn, such progression may result in an embolic shower from the fragmented lipid core, thrombosis, or dissection. With submaximal angioplasty, flow can be restored to relieve the patient's symptoms without creating the same severity of intimal disruption (and plaque destabilization) as seen with more aggressive angioplasty. Furthermore, balloon-induced fibrocellular proliferation may result in a thickened neointima, which may be protective during stent placement in the ensuing weeks. 34 Abundant histochemical evidence obtained in animal studies indicates that intimal healing and smooth muscle proliferation are active for 14 to 30 days after traumatic balloon angioplasty. 3, 39 Intravascular remodeling occurs in three phases: 1) an acute initiating phase in which platelets, thrombin, and leukocytes release biologically active mediators; 2) an intermediate phase in which activated medial smooth-muscle cells proliferate and migrate to the subintima; and 3) a chronic phase in which extracellular matrix production leads to remodeling. 44 We recommend waiting a minimum of 1 month between angioplasty and staged stent placement to allow for intimal healing. Attempts to navigate devices across unhealed lesions may result in release of embolic debris or iatrogenic dissection. As demonstrated by the patient in Case 5 in our series, careful angiographic evaluation of a lesion previously treated with angioplasty is essential. Occasionally, modest inflation with the angioplasty balloon alone is sufficient to provide durable endoluminal recanalization, thereby obviating the need for stent placement.
Modest Endoluminal Revascularization Improves Blood Flow
As objective methods for the measurement of CBF become increasingly available, it is now possible to measure the presence of misery perfusion (insufficient flow to meet the metabolic demands of the ischemic territory) and flow augmentation after treatment of the stenotic lesion. In a report by Derdeyn, et al., 10 the achievement of a residual stenosis rate of 40% after balloon angioplasty was sufficient to improve hypoperfusion and normalize the oxygen extraction ratio. Thus, perhaps patients with high-grade or unstable (symptomatic) lesions are best treated with balloon angioplasty for partial revascularization. These pa- tients would be readmitted for stent placement (pending angiographic findings) at a later date, when the lesion has healed from the angioplasty.
Because flow is proportional to the radius of the lumen to the fourth power (Poiseuille's equation), a small augmentation in lumen diameter may be sufficient, as demonstrated in reports by Derdeyn, et al., 10 and Uchiyama, et al., 43 to provide transient relief of ischemic symptoms. Other benefits of revascularization include reduced stroke risk as a result of normalization of oxygen extraction fraction and increased CBF.
14 In a study conducted by Uchiyama, et al., 43 positron emission tomography was used to demonstrate significant improvements in CBF and oxygen extraction ratio after stent-assisted angioplasty of a severe BA stenosis.
Other modalities of blood flow assessment, such as singlephoton emission computerized tomography, have been used to demonstrate successful flow augmentation after stent-assisted angioplasty for ischemia resulting from posterior circulation lesions.
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Risks Related to Intracranial Stent Placement
To date, various experiences with stent-assisted angioplasty of the VB circulation have been documented in several case reports and small retrospective series. 2, 13, 18, 22, 24, 27, 28, 32 In a recent review by Rasmussen, et al., 32 atherosclerotic lesions of the intracranial posterior circulation in eight patients were treated with endoluminal stent placement. These authors reported technical success, with only 7 to 28% residual stenosis. In one patient with a 99% 14-mm-long stenosis, the stent would not cross the lesion. This lesion was dilated with two angioplasty balloons, after which a stent was placed, resulting in a dissection and the patient's eventual death due to a subarachnoid hemorrhage. These authors concluded that the subarachnoid hemorrhage most likely resulted from rupture of the VA after the dissection.
Symptomatic, high-grade, long stenoses are the types of lesions that may be best suited for staged stent-assisted angioplasty (Fig. 1) . After multiple angioplasty treatments of the lesion, the VA in the case reported by Rasmussen, et al., likely had small dissections not readily appreciable on angiography. Allowing time for a normal fibrotic reaction to occur, during which the vessel can heal and "scar," might reduce the chance of vessel rupture or clinically relevant dissection resulting from stent placement immediately after angioplasty of such a tight lesion. In the aforementioned large cohort series, Connors and Wojak 9 stated that an angioplasty site should not be recrossed immediately after dilation because this maneuver has resulted in abrupt vessel occlusion. As demonstrated by Rasmussen, et al., 32 Gomez and colleagues, 12, 13 and others, 24 successful stent-assisted angioplasty may be feasible in most lesions without planned staging. For symptoms attributed to high-grade stenotic lesions, however, partial endoluminal revascularization with submaximal angioplasty alone followed by stent placement (if needed) at a later date may help reduce procedure-related morbidity.
In another series of VBA stent placement, two deaths occurred periprocedurally in patients with long, high-grade stenoses. 24 A third patient eventually died of a massive pontine infarct thought to be related to an embolic shower that occurred after stent deployment. In all but one patient with Mori Type A lesions (Ͻ 5 mm, concentric stenosis), no neurological procedural complications were noted. These data further corroborate that stent-assisted angioplasty of shorter lesions has a lower procedural risk and indicate that longer, high-grade stenoses may have fewer neurological complications after staged angioplasty and stent placement. A caveat about angioplasty of long, high-grade lesions is underscored by the results of Mori, et al., 26 in which a significant increase in procedure-related morbidity was observed after angioplasty of lesions they classified as Type C, or those that were longer than 10 mm, ectatic or tortuous, and/or occluded. For patients with Type C lesions, the procedure success rate was 33%, with one patient experiencing a procedure-related stroke and six others requiring bypass surgery. All patients with Type C lesions either suffered ipsilateral stroke or needed bypass surgery or repeated angioplasty.
Conclusions
On the basis of previous studies, increased morbidity and low procedure success rates may be associated with angioplasty (when it is the sole method of endoluminal revascularization) of long, tortuous, high-grade stenotic lesions of the intracranial circulation. 26, 29 In light of these findings, in conjunction with data that are available regarding lesion morphological characteristics in the coronary circulation, and normalization of CBF and metabolism after angiographically suboptimal angioplasty (residual stenosis of Ն 50%), perhaps the goal of angioplasty of long stenotic lesions (Mori Grade C lesions) should be to achieve modest luminal improvements (estimated residual stenosis of 50%) by use of undersized balloons and slow inflation techniques. 9 Restenosis rates are statistically significantly higher for Type C than for Type A lesions (Ͻ 5 mm, concentric). Perhaps the higher morbidity and restenosis rates seen in Type C lesions result from the fact that these are Type IV and V lesions, 36 which then progress rapidly to Type VI lesions due to balloon-induced surface disruptions. Therefore, partial angioplasty should not be the definitive treatment, but rather the initial stage for stent-assisted angioplasty. Clearly, there are insufficient data regarding restenosis rates for intracranial stent placement. With the development of newer coated cardiac stents, restenosis rates with the stent in place have declined from approximately 30% to 0% in some early coronary artery stent trials. 35 The data we have presented and the finding of no permanent neurological morbidity indicate a role for staged angioplasty and stent placement. It is important to note that the medical management and decision-making schema for these eight patients were based on the complex morphological features of their lesions. Only five patients, however, were treated in a staged fashion; the other three were not because of either vessel dissection, resolution of stenosis at the time of angiographic follow up, or our inability to navigate a stent successfully across vessel tortuosities. The fact that only five patients were treated should not detract from the fact that all eight patients were believed to be in a category in which staged stent placement could lower the risk of treating such complex lesions. Larger-scale studies involving multiple centers are needed to elucidate the mor-phological features of the lesions and the patient population most likely to benefit from staged treatment.
